Import your Google Finance portfolio into Sharesight
As you may have heard by now, Google has killed-off their Google Finance portfolio tracker. So if you managed to save/download a copy of your Google Finance portfolio data, you can easily import your existing Google Finance portfolio directly into Sharesight.
Sharesight is an award-winning portfolio tracker that DIY investors around the world rely on for performance, dividend, and tax reporting. It’s really much more than a Google Finance alternative – for a side-by-side comparison, check out the 4 ways Sharesight is better than Google Finance.
Importing your Google Finance portfolio into Sharesight is easy.
Essentially all you need to do is:
- Download your portfolio from Google Finance (as an OFX file)
- Upload it to Sharesight
Don’t worry -- you’ll be given the chance to review and edit your trade data. But once you’ve made any necessary adjustments, your Sharesight portfolio will be populated with your Google Finance portfolio. This will allow you to view your portfolio performance across various date ranges (something you can’t do with Google Finance):
Sharesight will even auto-populate your actual dividends (unlike Google Finance, who assume you only own 1 share’s worth):
To learn why Sharesight is more than just a Google Finance alternative, check out: 4 ways Sharesight is better than Google Finance.
Don't wait until it's too late. Sign up for a FREE Sharesight account and upload your Google Finance portfolio today!
FURTHER READING
See what’s inside your ETFs with Sharesight’s exposure report
See inside your ETFs and get the full picture of your investment portfolio's composition with Sharesight's exposure report.
How KmacD Financial streamlines reporting and saves time with Sharesight
We talk to financial planning firm KmacD Financial about how the Sharesight-AdviserLogic integration helps them save time and streamline client reporting.
Sharesight product updates – November 2023
The focus over the past month has been on implementing additional feature ideas relating to our new (beta) exposure report.